Primary Mode of Action Is A Primary Focus Of Combo Products Hearing
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent announcement that it is reconsidering jurisdiction for wound products indicates a problematic shift in the agency's interpretation of "primary mode of action," AdvaMed maintained at a June 24 public hearing to discuss the regulation of combination products containing live cellular components
You may also be interested in...
FDA Will Accept Primary Mode Of Action Definition Comments Until Jan. 24
Clarification of primary mode of action (PMOA) is a priority for the soon-to-be established Office of Combination Products, according to Mark Kramer, director of the agency's current combination product program within the FDA Office of the Ombudsman
FDA Will Accept Primary Mode Of Action Definition Comments Until Jan. 24
Clarification of primary mode of action (PMOA) is a priority for the soon-to-be established Office of Combination Products, according to Mark Kramer, director of the agency's current combination product program within the FDA Office of the Ombudsman
MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2